Pasithea Therapeutics Corp.

NasdaqCM KTTA

Pasithea Therapeutics Corp. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -1,614.06%

Pasithea Therapeutics Corp. EBT Margin is -1,614.06% for the Trailing 12 Months (TTM) ending September 30, 2024, a 75.09% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Pasithea Therapeutics Corp. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -6,478.35%, a -116.88% change year over year.
Pasithea Therapeutics Corp. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -2,987.07%.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqCM: KTTA

Pasithea Therapeutics Corp.

CEO	Dr. Tiago Reis Marques M.D., Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	1111 Lincoln Road
Employees	8
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Key trends

Past 5 years